Patents by Inventor Ping Tsui

Ping Tsui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220378230
    Abstract: The present application discloses a mannequin. The mannequin includes: a torso, upper limbs on both sides of the torso and a yawing device used for regulating the lateral swing of the upper limb being arranged at the joint between the upper limb and the torso. An upper limb fixing seat is arranged at the root of the upper limb. The yawing device includes: a yawing bracket hinged with the top of the upper limb fixing seat and a regulating piece with an inner end movable relative to the bottom of the yawing bracket. The outer end of the regulating piece being fixedly connected with the yawing bracket, and the movement of the regulating piece is used to drive the top of the upper limb fixing seat to swing relative to the yawing bracket, such that the upper limb is driven to swing.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 1, 2022
    Inventors: HO-SIANG HSIEH, LOK TING WONG, KAO HING PAUL LEE, KA PING TSUI
  • Publication number: 20220378229
    Abstract: The present application discloses a mannequin. The mannequin includes: a support frame; plates, being configured to enclose the shell of the torso, and comprising driving plates; circumference regulating devices, being configured to support the driving plate and driving it to move; the torso comprising a plurality of regulating regions provided with the driving plates, the plates further comprising driven plates capable of moving together with the driving plates when driven by the driving plates, and at least one of the plurality of regulating regions is provided with the driven plate. Relaxation and contraction of the overall outline of the torso can be achieved simply by controlling the movement of the plates by transmission devices, and the size of the chest, waist, abdomen and hip circumferences of the mannequin can be adjusted, thereby accurately simulating the figure of the human body and achieving high adjustment accuracy.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 1, 2022
    Inventors: Ho-Siang HSIEH, Lok Ting WONG, Kao Hing Paul LEE, Ka Ping TSUI
  • Publication number: 20220204602
    Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody or fusion protein thereof. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody fusion protein thereof.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 30, 2022
    Inventors: Wenchao Song, Takashi Miwa, Damodar Gullipalli, Sayaka Sato, Ping Tsui, Yingjie Zhu, Xihua Zhu
  • Publication number: 20220177556
    Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.
    Type: Application
    Filed: September 6, 2019
    Publication date: June 9, 2022
    Inventors: Wenchao Song, Takashi Miwa, Damodar Gullipalli, Ping Tsui, Sayaka Sato
  • Publication number: 20210355439
    Abstract: Disclosed are a medium for differentiating neural stem cells into oligodendrocyte precursors and a method for preparing oligodendrocyte precursors by using the medium. The medium does not contain exogenous factors, and can avoid the contamination of exogenous factors and differentiate oligodendrocyte precursors.
    Type: Application
    Filed: May 31, 2019
    Publication date: November 18, 2021
    Inventors: Yat Ping TSUI, Jiaxian WANG, Ying Shing CHAN, Kwok Yan Daisy SHUM, Lap Kei Kenneth WU, Guy LAM
  • Publication number: 20210147531
    Abstract: The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.
    Type: Application
    Filed: January 19, 2021
    Publication date: May 20, 2021
    Applicant: MEDIMMUNE LIMITED
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Patent number: 10919958
    Abstract: The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: February 16, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Publication number: 20210040194
    Abstract: The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.
    Type: Application
    Filed: October 14, 2020
    Publication date: February 11, 2021
    Applicant: MEDIMMUNE LIMITED
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ryan Fleming, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Publication number: 20210009957
    Abstract: Provided are a cardiomyocyte preparation, a preparation method therefor and the use of the preparation in treating heart failure. The cardiomyocyte preparation comprises cardiomyocytes and fibroblasts, differentiated from pluripotent stem cells, wherein the concentration of the cardiomyocytes in the cardiomyocyte preparation is 0.75×107-1.0×109 cells/mL, and the content of the cardiomyocytes is higher than 80% while the content of the fibroblasts is not higher than 20%. The cardiomyocyte preparation can improve cardiac ejection fraction and left ventricular fractional shortening, and increase the thickness of the left ventricular inner wall.
    Type: Application
    Filed: December 19, 2019
    Publication date: January 14, 2021
    Inventors: Jiaxian WANG, Qian WANG, Yat Ping TSUI, Xiao XU
  • Patent number: 10836819
    Abstract: The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: November 17, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ryan Fleming, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Publication number: 20200277381
    Abstract: Provided herein are antibodies specific for integrin ?v?8 that change the conformation of ?8 so that, upon binding, the ability of ?v?8 to induce release of active, mature TGF? peptide is inhibited.
    Type: Application
    Filed: March 24, 2020
    Publication date: September 3, 2020
    Inventors: Stephen NISHIMURA, Anthony CORMIER, Jody Lynn BARON, James D. MARKS, Lynne MURRAY, Ping TSUI, Yanli WU, Jianlong Lou
  • Publication number: 20200164069
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Application
    Filed: February 5, 2020
    Publication date: May 28, 2020
    Applicant: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Patent number: 10588969
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 17, 2020
    Assignee: Boston Pharmaceuticals, Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Publication number: 20200071423
    Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 5, 2020
    Inventors: PING TSUI, MARTIN BORROK, WILLIAM DALL'ACQUA, YANLI WU, NURTEN BEYAZ-KAVUNCU
  • Publication number: 20190202903
    Abstract: The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.
    Type: Application
    Filed: August 22, 2017
    Publication date: July 4, 2019
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Publication number: 20190194308
    Abstract: The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.
    Type: Application
    Filed: August 22, 2017
    Publication date: June 27, 2019
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ryan Fleming, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Publication number: 20190082762
    Abstract: Provided is an intelligent breast adjustment model. The model includes a model main structure provided with a pressure sensor and a model periphery structure provided on the model main structure. The model main structure includes an upper portion, a middle portion and a lower portion. A first motor of the middle portion controls an up and down movement of a left breast model through a first gear. A second motor of the middle portion controls an up and down movement of a right breast model through a second gear, and a third motor of the middle portion simultaneously controls a left and right movement of the left breast model and the right breast model through a drive structure. A method for assembling the intelligent breast adjustment model is disclosed.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Inventors: Chee Kooi CHAN, Lok Ting WONG, Wai Chau HON, Ka Ping TSUI
  • Publication number: 20180318416
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Application
    Filed: June 11, 2018
    Publication date: November 8, 2018
    Applicant: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Publication number: 20180258178
    Abstract: Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 13, 2018
    Inventors: Ping Tsui, Martin Borrok, II, William Dall'Acqua
  • Patent number: 10022443
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 17, 2018
    Assignee: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman